| P50 | author | Alberto Bosi | Q56798509 |
| P2093 | author name string | Luca Nassi | |
| | Luigi Rigacci | |
| | Renato Alterini | |
| | Valentina Carrai | |
| | Silvia Mappa | |
| | Franco Bernardi | |
| P2860 | cites work | A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project | Q28251216 |
| | Reporting results of cancer treatment | Q29620070 |
| | Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer | Q32073515 |
| | Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 |
| | Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. | Q34429779 |
| | Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy | Q34429785 |
| | Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies | Q34563378 |
| | Anthracycline cardiotoxicity | Q36624983 |
| | Liposomal doxorubicin | Q41262422 |
| | Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion | Q42263291 |
| | CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 |
| | Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma | Q43869754 |
| | Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. | Q44895890 |
| | Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response | Q44958703 |
| | Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. | Q46453483 |
| | Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma | Q46645702 |
| | Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor | Q68546842 |
| P433 | issue | 4 | |
| P921 | main subject | doxorubicin | Q18936 |
| | rituximab | Q412323 |
| P304 | page(s) | 198-203 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Hematological Oncology | Q15762617 |
| P1476 | title | Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines | |
| P478 | volume | 25 | |